Dataset Information

Autonomy of patients with type 2 diabetes with an insulin pump device: is it predictable?

ABSTRACT: Insulin pump therapy may be offered to patients with type 2 diabetes that is not controlled by multiple daily injections. Patients with type 2 diabetes may suffer from unrecognized cognitive disabilities, which may compromise the use of a pump device.To predict patient autonomy, we evaluated 39 patients with type 2 diabetes from our database (n = 143) after continuous subcutaneous insulin infusion (CSII) initiation using (1) an autonomy questionnaire evaluating the patient's cognitive and operative capacities for CSII utilization, (2) the Montreal Cognitive Assessment (MOCA) for the detection of mild cognitive disabilities, (3) the Hospital Anxiety and Depression Scale (HADS) for the detection of anxiety and depression, and (4) the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Patients were selected to constitute 3 groups matched for age, with different degrees of autonomy at discharge after the initial training program: complete (n = 13), partial (n = 13), or no autonomy (n = 13).The satisfaction level with the pump device was high. At the last follow-up visit, only 23% of patients did not reach complete autonomy. The autonomy score correlated fairly with the MOCA score (R = 0.771, P < .001). A receiver operating characteristic (ROC) analysis showed that at a cut-off score of 24, the MOCA identified autonomous versus dependent patients at long-term follow-up (area under the ROC curve [AUC], 0.893; sensitivity, 81%; specificity, 81%). The HADS correlated negatively with the autonomy score, and the sociocultural level also influenced autonomy with pump utilization.Patients with type 2 diabetes with partial autonomy at discharge may progress to complete autonomy. The MOCA and HADS may help predict a patient's ability to manage with a pump device.

SUBMITTER: Reznik Y

PROVIDER: S-EPMC4764221 | biostudies-other | 2014 Jul

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Autonomy of patients with type 2 diabetes with an insulin pump device: is it predictable?

Reznik Yves Y Morello Rémy R Zenia Amel A Morera Julia J Rod Anne A Joubert Michael M

Journal of diabetes science and technology 20140430 4

<h4>Background</h4>Insulin pump therapy may be offered to patients with type 2 diabetes that is not controlled by multiple daily injections. Patients with type 2 diabetes may suffer from unrecognized cognitive disabilities, which may compromise the use of a pump device.<h4>Methods</h4>To predict patient autonomy, we evaluated 39 patients with type 2 diabetes from our database (n = 143) after continuous subcutaneous insulin infusion (CSII) initiation using (1) an autonomy questionnaire evaluating ...[more]

PMID: 24876438

Similar Datasets

Project description:BACKGROUND:This prospective single-center study recruited insulin-resistant continuous subcutaneous insulin infusion (CSII) therapy-naive patients with type 2 diabetes (T2D) using insulin analog-based multiple daily injections (MDI) therapy and metformin. METHODS:A total of 23 individuals with T2D (70% male), aged a mean?±?standard deviation 57.2?±?8.03 years, with body mass index of 36.2?±?7.02?kg/m2, diabetes duration of 13.3?±?4.64 years, and HbA1c of 10.0%?±?1.05% were randomly assigned to a CSII arm or an MDI continuation arm to explore glucose control, weight loss, total daily insulin dose (TDD), and insulin resistance. Insulin dosing was optimized over a 2-month run-in period. RESULTS:At 6 months, patients assigned to the CSII arm achieved a significant mean HbA1c reduction of -0.9% (95% confidence interval [CI]?=?-1.6, -0.1), while reducing their TDD by -29.8?±?28.41?U/day (33% of baseline [92.1?±?20.35?U/day]) and achieving body mass (BM) reduction of -0.8?±?5.61?kg (0.98% of baseline [104.8?±?16.15?kg]). MDI patients demonstrated a nonsignificant HbA1c reduction of -0.3% (95% CI?=?-0.8, 0.1) with a TDD reduction of 5% from baseline (99.0?±?25.25?U/day to 94.3?±?21.25?U/day), and a BM reduction of -1.0?±?2.03?kg (0.99% of baseline [108.9?±?20.55?kg]). After 6 months, the MDI arm crossed over to CSII therapy. At 12 months, patients continuing CSII demonstrated an additional mean 0.7% HbA1c reduction with 54.6% achieving HbA1c<8%. The final TDD reduction was -9.7?U/day in comparison to baseline; BM increased by 1.1?±?6.5?kg from baseline. The MDI patients that crossed to CSII showed an HbA1c reduction of -0.5%?±?1.04%, HbA1c response rate of 27.3%, a TDD reduction of -17.4?±?21.06?U/day, and a BM reduction of -0.3?±?3.39?kg. Diabetic ketoacidosis or severe hypoglycemia did not occur in either arm. CONCLUSION:CSII therapy safely and significantly improved metabolic control with less insulin usage, with no sustainable reduction of BM, blood pressure, and lipid profile, in insulin-resistant T2D patients. Treatment adherence and satisfaction in these patients were excellent.

Dataset Information

Autonomy of patients with type 2 diabetes with an insulin pump device: is it predictable?

Publications

Autonomy of patients with type 2 diabetes with an insulin pump device: is it predictable?

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure